Optipharm.CO.LTD (153710) - Total Liabilities

Latest as of June 2026: ₩15.42 Billion KRW ≈ $10.45 Million USD

Based on the latest financial reports, Optipharm.CO.LTD (153710) has total liabilities worth ₩15.42 Billion KRW (≈ $10.45 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 153710 long-term investments to assets to see how much of total assets are deployed in long-term investments.

Optipharm.CO.LTD - Total Liabilities Trend (2015–2025)

This chart illustrates how Optipharm.CO.LTD's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Optipharm.CO.LTD.

Optipharm.CO.LTD Competitors by Total Liabilities

The table below lists competitors of Optipharm.CO.LTD ranked by their total liabilities.

Company	Country	Total Liabilities
Genie Music Corporation KQ:043610	Korea	₩115.36 Billion
Whitbread PLC LSE:WTB	UK	GBX6.43 Billion
Bengang Steel Plates Co Ltd SHE:200761	China	HK$40.10 Billion
Halcyon Technology Public Company Limited BK:HTECH	Thailand	฿304.79 Million
Ado Optronics TWO:3516	Taiwan	NT$1.23 Billion
Pancontinental Energy NL AU:PCL	Australia	AU$580.18K
Werewolf Therapeutics Inc NASDAQ:HOWL	USA	$7.86 Million
Health In Tech, Inc. Class A Common Stock NASDAQ:HIT	USA	$7.36 Million

Liability Composition Analysis (2015–2025)

This chart breaks down Optipharm.CO.LTD's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Optipharm.CO.LTD to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.16	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.63	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.39	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Optipharm.CO.LTD's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Optipharm.CO.LTD (2015–2025)

The table below shows the annual total liabilities of Optipharm.CO.LTD from 2015 to 2025.

Year	Total Liabilities	Change
2025-12-31	₩15.37 Billion ≈ $10.42 Million	-3.84%
2024-12-31	₩15.98 Billion ≈ $10.83 Million	+13.11%
2023-12-31	₩14.13 Billion ≈ $9.58 Million	+16.10%
2022-12-31	₩12.17 Billion ≈ $8.25 Million	+19.17%
2021-12-31	₩10.21 Billion ≈ $6.92 Million	+35.43%
2020-12-31	₩7.54 Billion ≈ $5.11 Million	+23.42%
2019-12-31	₩6.11 Billion ≈ $4.14 Million	-15.07%
2018-12-31	₩7.20 Billion ≈ $4.88 Million	+1.97%
2017-12-31	₩7.06 Billion ≈ $4.78 Million	-0.27%
2016-12-31	₩7.08 Billion ≈ $4.79 Million	-46.06%
2015-12-31	₩13.12 Billion ≈ $8.89 Million	--

About Optipharm.CO.LTD

KQ:153710 Korea Diagnostics & Research

Market Cap

$46.92 Million

₩69.24 Billion KRW

Market Cap Rank

#22227 Global

#1404 in Korea

Share Price

₩4720.00

Change (1 day)

+0.00%

52-Week Range

₩4260.00 - ₩6200.00

All Time High

₩28900.00